CLEVELAND, March 06, 2023 (GLOBE NEWSWIRE) -- NovelMed Therapeutics announced today that NM3086, the lead clinical asset in its Properdin-associated Alternative Pathway (AP) program, demonstrated ...

本研究针对子痫前期和早产等妊娠并发症中补体系统失调的机制问题，通过检测脐带血中C1q、C4、C3、MBL、Factor H和properdin等补体成分浓度，发现并发症组C1q、C4、C3和MBL浓度显著低于足月组，而properdin在子痫前期组升高。结果提示胎儿补体系统随妊娠进展逐渐成熟 ...

After seven years of intense research, a research group from Aarhus University has succeeded - through an interdisciplinary collaboration - in understanding why a very extended structure is important ...

CLEVELAND, June 05, 2023 (GLOBE NEWSWIRE) -- NovelMed Therapeutics, Inc. announced today topline results from First-in-Human Phase I clinical trial of its complement blocker monoclonal anti-Properdin ...

Novelmed Therapeutics Inc. has reported topline results with its lead anti-properdin antibody NM-3086 in a rabbit model of paroxysmal nocturnal hemoglobinuria (PNH). NM-3086 is a potent, ...

NM5072 is a potential first-in-class monoclonal antibody that selectively blocks properdin, a protein of the complement alternative pathway. The Food and Drug Administration (FDA) has granted Orphan ...

Alper, C.A., Boenisch, T., and Watson, L. 1972. Genetic polymorphism in human glycine-rich beta-glycoprotein.J. Exp. Med. 135: 68–80.

A research group has succeeded in understanding why a very extended structure is important for an essential protein from the human immune system. The new results offer new opportunities for adjusting ...